CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock?

CorMedix (CRMD) shares rallied 5.1% in the last trading session to close at $11.62. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 29.6% loss over the past four weeks.

The sudden price rise can be attributed to growing investor optimism related to the initial sales uptake of the company’s lead product, DefenCath (taurolidine and heparin), which was approved by the FDA in November 2023 as the first catheter lock solution.

This pharmaceutical and medical device company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +168%. Revenues are expected to be $36.2 million, up 4369.1% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For CorMedix, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CRMD going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

CorMedix is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Illumina (ILMN), finished the last trading session 2.5% higher at $104.61. ILMN has returned 11.5% over the past month.

For Illumina, the consensus EPS estimate for the upcoming report has changed -0.2% over the past month to $1.02. This represents a change of +183.3% from what the company reported a year ago. Illumina currently has a Zacks Rank of #3 (Hold).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research